1. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol 3: 1683-1691, 2017.
2. El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127 (Suppl 1): S27-$34, 2004.
3. Munoz N and Bosch X: Epidemiology of hepatocellular carci-noma. In: Neoplasms of the liver. Okuda K and Ishak KG (eds). Springer, Tokyo, p3, 1989.
4. Davila JA, Morgan RO, Shaib Y, McGlynn KA and El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocel-lular carcinoma: A population-based study. Gastroenterology 127: 1372-1380, 2004.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Sanoff HK, Chang Y, Lund JL, O'Neil BH and Dusetzina SB: Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 21: 1113-1120, 2016.
7. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014.
8. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto IP, Mellado B, et al: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16: 1473-1482, 2015.
9. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocel-lularcarcinoma: A randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.
10. Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y and Matsui J: Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling path-ways in human hepatocellular carcinoma models. Cancer Med 7: 2641-2653, 2018.
11. Morishita A, Iwama H, Fujihara S, Sakamoto T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T and Masaki T: MicroRNA profiles in various hepatocellular carcinoma cell lines. Oncol Lett 12: 1687-1692, 2016.
12. Liang LH and He XH: Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin 32: 1311-1320, 2011.
13. Miyata M, Morishita A, Sakamoto T, Katsura A, Kato K, * Nishioka T, Toyota Y, Fujita K, Maeda E, Nomura T, et al: MicroRNA profiles in cisplatin-induced apoptosis of hepatocel-lular carcinoma cells. Int J Oncol 47: 535-542, 2015.
14. Futami T, Okada H, Kihara R, Kawase T, Nakayama A, Suzuki I, Kameda M, Shindoh N, Terasaka 'T, Hirano M and Kuromitsu S: ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma. Mol Cancer Ther 16: 68-75, 2017.
15. Kim SY, Kim SM, Chang HJ, Kim BW, Lee YS, Park CS, Park KC and Chang HS: SoLAT (sorafenib lenvatinib alternating treatment); A new treatment protocol with alternating sorafenib and lenvatinib for refractory thyroid cancer. BMC Cancer 18: 956, 2018.
16. Ogasawara S, Mihara Y, Kondo R, Kusano H, Akiba J and Yano H: Antiproliterative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res 39: 5973-5982, 2019.
17. Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L and Teng Y: FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3B/ ß-catenin signaling cascade via FGFR4 activation. Oncotarget 7: 13575-13586, 2016.
18. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F, Pascale RM, Prieto J, et al: Regulation of amphiregulin gene expression by B-catenin signaling in human hepatocellular carcinoma cells: A novel crosstalk between FGF19 and the EGFR system. PLoS One 7: e52711, 2012.
19. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY and Cheng AL: Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707, 2008.
20. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ and Cheng AL: Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52: 88-95, 2010.
21. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A and Asada M: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465, 2008.
22. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe I, Wakabayashi T, Uenaka T and Asada M: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664-671, 2008.
23. Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, er al: E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 15: 7229-7237, 2009.
24. Jing C, Gao Z, Wang R, Yang Z., Shi B and Hou P: Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res 7: 903-912, 2017.
25. Han Q, Zhao H, Jiang Y, Yin C and Zhang J: HCC-derived exosomes: critical player and target for cancer immune escape. Cells 8: 558, 2019.
26. Yu LX, Zhang BL, Yang Y, Wang MC, Lei GL, Gao Y, Liu H, Xiao CH, Xu JJ, Qin H, et al: Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepato-cellular carcinoma patient-derived cell models. Oncol Rep 41: 257-269, 2019.
27. Deng M, Zeng C, Lu X, He X, Zhang R, Qiu Q, Zheng G, Jia X, Liu H and He Z: miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. Cancer Let 403: 175-185, 2017.
28. Sun R, Liu Z, Tong D, Yang Y, Guo B, Wang X, Zhao L and Huang C: miR-491-Sp, mediated by Foxil, functions as a tumor suppressor by targeting Wnt3a/ß-catenin signaling in the development of gastric cancer. Cell Death Dis 8: e2714, 2017.
29. Lu L, Cai M, Peng M, Wang F and Zhai X: miR-491-5p functions as a tumor suppressor by targeting IGF2 in colorectal cancer. Cancer Manag Res 11: 1805-1816, 2019.
30. Lv QL, Du H, Liu YL, Huang YT, Wang CH, Zhang X, Chen SH and Zhou HH: Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. Oncol Rep 38: 959-966, 2017.
31. Lu Y, Yang L, Qin A, Qiao Z, Huang B, Jiang X and Wu J: miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma. Biochem Biophys Res Commun 522: 716-723, 2020.
論文の公開元へ
